BioWorld

May 14, 2008

Cash-Strapped Iomai Jumps on $189M Buyout Bid by Intercell

Shares of Iomai Corp. surged more than 117 percent after the firm agreed to be acquired by Austrian vaccines maker Intercell AG in a deal valued at about $189 million. (BioWorld Today) Read More

KAI, BMS Join Forces in $227M Heart Drug Deal

Novacea Slashing Jobs Following Ill-Fated Trial

NewCo News: Making Fossil Fuel Supplies, but Leaving Out the Fossils

Other News To Note

Earnings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...